Watson Pulls Prochieve From Guidance, But Pushes For Approval
By
Jessica Merrill / Email the Author / “The Pink Sheet” DAILY Jan. 25, 2012
Word Count: 1073 / Article # 14120124006
Executive Summary
Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.